Improving postapproval drug safety surveillance: Getting better information sooner

Sean Hennessy, Brian L. Strom

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Adverse drug events (ADEs) are an important public health concern, accounting for 5% of all hospital admissions and two-thirds of all complications occurring shortly after hospital discharge. There are often long delays between when a drug is approved and when serious ADEs are identified. Recent and ongoing advances in drug safety surveillance include the establishment of government-sponsored networks of population databases, the use of data mining approaches, and the formal integration of diverse sources of drug safety information. These advances promise to reduce delays in identifying drug-related risks and in providing reassurance about the absence of such risks.

Original languageEnglish (US)
Pages (from-to)75-87
Number of pages13
JournalAnnual Review of Pharmacology and Toxicology
StatePublished - Jan 6 2015

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology


  • Adverse drug reaction reporting systems
  • Pharmacoepidemiology
  • Postmarketing
  • Precision medicine
  • Prediction in pharmacology
  • Product surveillance


Dive into the research topics of 'Improving postapproval drug safety surveillance: Getting better information sooner'. Together they form a unique fingerprint.

Cite this